Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase

Journal of Virology

Volumn 86, Issue 16, 2012, Pages 8422-8431

  Xu, Hong Tao ^a   Oliveira, Maureen ^a   Quashie, Peter K ^a,b   McCallum, Matthew ^a,c   Han, Yingshan ^a   Quan, Yudong ^a   Brenner, Bluma G ^a   Wainberga, Mark A ^b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYNUCLEOSIDE TRIPHOSPHATE; EMTRICITABINE; LAMIVUDINE; NUCLEOSIDE TRIPHOSPHATE; PROTEIN P51; PROTEIN P66; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN INTERACTION; PROTEIN POLYMERIZATION; PROTEIN SUBUNIT; TISSUE CULTURE; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTANT PROTEINS; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84865099478     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00271-12     Document Type: Article

References (57)

1. Andries K, et al. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
2. Arts EJ, et al. 1994. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269:14672-14680.
3. Asahchop EL, et al. 2011. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 55:600-607.
4. Azijn H, et al. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTIresistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
5. Back NK, Berkhout B. 1997. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 41:2484-2491.
6. Back NK, et al. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
7. Balzarini J, et al. 2001. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J. Virol. 75:5772-5777.
8. Balzarini J, et al. 1994. Sensitivity of (138 Glu¡Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 201: 1305-1312.
9. Blower S, Bodine E, Kahn J, McFarland W. 2005. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19:1-14.
10. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. 2001. Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med. 7:1016-1020.
11. Boyer PL, Ding J, Arnold E, Hughes SH. 1994. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:1909-1914.
12. Buckton AJ, et al. 2011. Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in aUK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med. 12:250-254.
13. Cheynier R, Gratton S, Vartanian JP, Meyerhans A, Wain-Hobson S. 1997. G¡A hypermutation does not result from polymerase chain reaction. AIDS Res. Hum. Retroviruses 13:985-986.
14. Diallo K, et al. 2003. The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates. Antimicrob. Agents Chemother. 47:2376-2379.
15. Diallo K, Gotte M, Wainberg MA. 2003. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 47:3377-3383.
16. Diamond TL, et al. 2004. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J. Biol. Chem. 279:51545-51553.
17. Esnouf RM, et al. 1997. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. U. S. A. 94:3984-3989.
18. Gao L, et al. 2008. Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J. Biol. Chem. 283:9196-9205.
19. Goff SP. 1990. Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. 3:817-831.
20. Howard KJ, Frank KB, Sim IS, Le Grice SF. 1991. Reconstitution and properties of homologous and chimeric HIV-1.HIV-2 p66.p51 reverse transcriptase.J. Biol. Chem. 266:23003-23009.
21. Hu Z, Kuritzkes DR. 2011. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J. Virol. 85:11309-11314.
22. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM. 2003. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77:1512-1523.
23. Imamichi T, et al. 2000. Relative replication fitness of a high-level 3=-azido-3=-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr¡Gly) at codon 69. J. Virol. 74:10958-10964.
24. Jamburuthugoda VK, et al. 2008. Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. J. Biol. Chem. 283:9206-9216.
25. Janssen PA, et al. 2005. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 48:1901-1909.
26. Johnson VA, et al. 2011. 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 19:156-164.
27. Julias JG, Pathak VK. 1998. Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J. Virol. 72:7941-7949.
28. Kati WM, Johnson KA, Jerva LF, Anderson KS. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997.
29. Keulen W, Back NK, van Wijk A, Boucher CA, Berkhout B. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3346-3350.
30. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
31. Kulkarni R, et al. 2012. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness. J. Acquir. Immune Defic. Syndr. 59:47-54.
32. Kulkarni SS, et al. 2009. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 385:505-520.
33. Le Grice SF, Cameron CE, Benkovic SJ. 1995. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262:130-144.
34. Macarthur RD. 2011. Clinical trial report: TMC278 (rilpivirine) versus efavirenz as initial therapy in treatment-naive, HIV-1-infected patients. Curr. Infect. Dis. Rep. 13:1-3.
35. Menendez-Arias L, Betancor G, Matamoros T. 2011. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Res. 92:139-149.
36. Meyerhans A, et al. 1994. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J. Virol. 68:535-540.
37. Nikolenko GN, Svarovskaia ES, Delviks KA, Pathak VK. 2004. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J. Virol. 78:8761-8770.
38. Oliveira M, Brenner BG, Wainberg MA. 2009. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol. Biol. 485:427-433.
39. Pandey PK, et al. 2002. Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem. 3:18. doi:10.1186/1471-2091-3-18.
40. Pandey PK, Kaushik N, Talele TT, Yadav PN, Pandey VN. 2001. The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 40:9505-9512.
41. Quan Y, et al. 2003. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res. Hum. Retroviruses 19:743-753.
42. Reutrakul V, et al. 2010. Anti-HIV-1 and anti-inflammatory lupanes from the leaves, twigs, and resin of Garcinia hanburyi. Planta Med. 76: 368-371.
43. Richmond NJ, et al. 2006. GALAHAD. 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput. Aided Mol. Des. 20:567-587.
44. Schuckmann MM, et al. 2010. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. J. Biol. Chem. 285:38700-38709.
45. Smerdon SJ, et al. 1994. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 91:3911-3915.
46. Tambuyzer L, et al. 2010. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirinecontaining regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res. Hum. Retroviruses 26:1197-1205.
47. Turner D. 2011. Does the M184V resistance mutation in reverse transcriptase reduce HIV transmission? HIV Med. 12:193-194.
48. Turner D, Brenner B, Wainberg MA. 2003. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin. Diagn. Lab. Immunol. 10:979-981.
49. Upadhyay A, Pandey N, Mishra CA, Talele TT, Pandey VN. 2010. A single deletion at position 134, 135, or 136 in the beta 7-beta 8 loop of the p51 subunit of HIV-1 RT disrupts the formation of heterodimeric enzyme. J. Cell. Biochem. 109:598-605.
50. Van Cor-Hosmer SK, Daddacha W, Kim B. 2010. Mechanistic interplay among the M184I HIV-1 reverse transcriptase mutant, the central polypurine tract, cellular dNTP concentrations and drug sensitivity. Virology 406:253-260.
51. Wainberg MA. 2004. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti Infect. Ther. 2:147-151.
52. Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG. 2011. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J. Antimicrob. Chemother. 66:2346-2349.
53. Xu H, et al. 2009. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob. Agents Chemother. 53:4667-4672.
54. Xu HT, et al. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J. Virol. 85:11300-11308.
55. Xu HT, Oliveira M, Quan Y, Bar-Magen T, Wainberg MA. 2010. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. J. Antimicrob. Chemother. 65:2291-2299.
56. Xu HT, et al. 2010. Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C. Retrovirology 7:80. doi:10.1186/1742-4690-7-80.
57. Yap SH, et al. 2007. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 4:e335. doi:10.1371/journal.pmed.0040335.